Cure of Burkitt's lymphoma. Ten-year follow-up of 157 Ugandan patients.
192 Ugandan patients with Burkitt's lymphoma were treated with various regimens containing high-dose cyclophosphamide. 21 patients died during induction therapy, and 14 died after partial responses. Of 157 patients who responded completely to treatment, 16 were lost to follow-up (10 in 69 died and 72 (51%) are alive and disease-free. 31 of the long-term survivors have relapsed at least once and have been successfully retreated. Overall, 34 surviving patients had central-nervous-system involvement, also successfully treated. It is concluded that Burkitt's lymphoma is curable in at least 50% of patients, and that relapse and central-nervous-system involvement are not incompatible with long survival.
D001500:BCG Vaccine / Q000008:administration & dosage; D002051:Burkitt Lymphoma / Q000401:mortality / Q000628:therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D008577:Meningeal Neoplasms / Q000401:mortality / Q000628:therapy; D008727:Methotrexate / Q000008:administration & dosage; D011897:Random Allocation; D012075:Remission, Spontaneous; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
D001500:BCG Vaccine; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D008727:Methotrexate